Related Experiment Video
Updated: Feb 24, 2026
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylase inhibitors as novel anti-inflammatory agents
1Airways Disease Section, National Heart and Lung Institute, Imperial College London, Dovehouse St, London SW3 6LY, UK. ian.adcock@imperial.ac.uk
Abstract:
Histone acetylation regulates inflammatory gene expression and also plays a role in diverse functions such as DNA repair and cell proliferation. Changes in histone acetylation patterns have been reported in many human diseases, particularly cancer, and investigators have used histone deacetylase inhibitors (eg, suberoylanilide hydroxamic acid and MS-275) against many malignancies. In vitro and in vivo data in a number of cell types and animal models of disease indicate that selective histone deacetylase inhibitors may have the potential to act as anti-inflammatory agents possibly acting through non-histone proteins. More evidence is required concerning the long-term safety of these agents, for example, lung destruction, and in comparison with currently used therapies.
Insights
Histone deacetylase inhibitors show potential as anti-inflammatory agents, possibly by affecting non-histone proteins. Further research is needed to confirm their long-term safety and compare them to existing therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Histone acetylation regulates key cellular processes including inflammatory gene expression, DNA repair, and cell proliferation.
- Aberrant histone acetylation patterns are implicated in various human diseases, notably cancer.
- Histone deacetylase inhibitors (HDACi) are utilized in treating malignancies.
Purpose of the Study:
- To explore the potential of selective histone deacetylase inhibitors (HDACi) as anti-inflammatory agents.
- To investigate the mechanisms of action, including potential interactions with non-histone proteins.
- To highlight the need for further safety and efficacy evaluations.
Main Methods:
- In vitro studies across various cell types.
- In vivo studies using animal models of disease.
- Review of existing data on HDACi efficacy and safety.
Main Results:
- Selective HDACi demonstrate potential as anti-inflammatory agents.
- Evidence suggests these agents may act via non-histone protein modulation.
- Concerns regarding long-term safety, such as lung toxicity, require further investigation.
Conclusions:
- Selective histone deacetylase inhibitors show promise as anti-inflammatory therapies.
- Further research is essential to elucidate their precise mechanisms and long-term safety profiles.
- Comparative studies against current therapies are necessary to establish their clinical utility.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...